Prophylactic mesh reinforcement at emergency midline laparotomy: a systematic review and meta-analysis with pre-specified subgroup analysis of contaminated and dirty abdominal wounds (CDC Class III–IV)
摘要
To evaluate the efficacy and safety of prophylactic mesh reinforcement (PMR) at the closure of emergency midline laparotomy (EML), with a pre-specified subgroup analysis of contaminated and dirty wounds (CDC class III–IV).
MethodsPRISMA 2020-compliant review (PROSPERO CRD420261324766; OSF 10.17605/OSF.IO/ZX2BG; amendments registered before data extraction). PubMed/MEDLINE, Embase, Cochrane CENTRAL, Scopus and Web of Science were searched (January 2015–March 2026). RCTs and comparative cohort studies reporting incisional hernia (IH) at ≥ 12 months were eligible; bias was assessed with ROB-2/ROBINS-I. Random-effects meta-analysis used the REML estimator with Hartung–Knapp–Sidik–Jonkman correction. A pre-specified Borenstein interaction test compared CDC class I–II with III–IV; trial sequential analysis (TSA) and GRADE were applied.
ResultsFive studies (4 RCTs; 1 cohort; n = 617) were included. PMR was associated with a reduction in IH (pooled OR 0.221, 95% CI 0.122–0.402 [Knapp–Hartung]; 0.101–0.483 under the conservative truncated variant; I2 = 0%); because control-arm event rates exceeded 10%, this corresponds to an approximate RR of ~ 0.36 (0.28–0.38). The RCT-only analysis was concordant (OR 0.179, 95% CI 0.074–0.435). TSA gave an accrued information size of 617 versus a required ~ 151 (409%), interpreted only as numerical sufficiency, not firm evidence. The CDC interaction was non-significant and underpowered (z = 0.327, p = 0.743). Seroma was significantly increased (k = 4; OR 3.980, 95% CI 1.924–8.234; 1.06–14.94 under the conservative variant), whereas deep SSI was non-significant and underpowered (OR 0.991). GRADE: LOW to VERY LOW.
ConclusionPMR at EML closure was associated with a consistent IH reduction across CDC classes; however, contaminated-wound evidence is sparse, the subgroup interaction is exploratory, non-significant and underpowered, and the safety profile — particularly deep SSI — remains uncharacterized. Seroma was significantly increased. Given LOW–VERY LOW certainty, these hypothesis-generating findings should not change practice and support an adequately powered multicentre RCT in CDC class III–IV wounds.
Trial registration: PROSPERO CRD420261324766 (registered 23 February 2026); OSF Registrieshttps://doi.org/10.17605/OSF.IO/ZX2BG.